Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 5, 2011, Pages 1163-1176

  Theiss, Arianne L ^a,c   Laroui, Hamed ^a   Obertone, Tracy S ^a   Chowdhury, Indrajit ^b   Thompson, Winston E ^b   Merlin, Didier ^a   Sitaraman, Shanthi V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c Division of Digestive Diseases   (United States)

Author keywords

animal models of IBD; colitis; gene therapy; nanotechnology

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; ENEMA; MYELOPEROXIDASE; NANOPARTICLE; POLYLACTIC ACID; PROHIBITIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ANIMALS; CACO-2 CELLS; COLITIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NANOPARTICLES; NF-KAPPA B; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953850342     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21469     Document Type: Article

References (28)

1. Danese S, Fiocchi C., Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006; 12: 4807-4812. (Pubitemid 44323204)
2. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol. 2004; 286: G367-G376. (Pubitemid 38250308)
3. Ali S, Mann DA., Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct. 2004; 22: 67-79. (Pubitemid 38316021)
4. Steinbrecher KA, Harmel-Laws E, Sitcheran R, et al. Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol. 2008; 180: 2588-2599.
5. Artal-Sanz M, Tsang WY, Willems EM, et al. The mitochondrial prohibitin complex is essential for embryonic viability and germline function in Caenorhabditis elegans. J Biol Chem. 2003; 278: 32091-32099. (Pubitemid 37048398)
6. Nijtmans LG, de Jong L, Artal Sanz M, et al. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000; 19: 2444-2451. (Pubitemid 30323534)
7. Dell'Orco RT, McClung JK, Jupe ER, et al. Prohibitin and the senescent phenotype. Exp Gerontol. 1996; 31: 245-252. (Pubitemid 26079676)
8. Jupe ER, Liu XT, Kiehlbauch JL, et al. Prohibitin antiproliferative activity and lack of heterozygosity in immortalized cell lines. Exp Cell Res. 1995; 218: 577-580.
9. Joshi B, Rastogi S, Morris M, et al. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J. 2007; 401: 155-166. (Pubitemid 46114609)
10. Wang S, Fusaro G, Padmanabhan J, et al. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene. 2002; 21: 388-396.
11. Wang S, Nath N, Adlam M, et al. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene. 1999; 18: 3501-3510. (Pubitemid 29317345)
12. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics. 2006; 6: 5322-5331.
13. Theiss AL, Idell RD, Srinivasan S, et al. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 2007; 21: 197-206. (Pubitemid 46052557)
14. Theiss AL, Jenkins AK, Okoro NI, et al. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Mol Biol Cell. 2009; 20: 4412-4423.
15. Theiss AL, Vijay-Kumar M, Obertone TS, et al. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology. 2009; 137: 199-208.
16. Chowdhury I, Xu W, Stiles JK, et al. Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology. 2007; 48: 206-217. (Pubitemid 46021452)
17. Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010; 138: 843-853.
18. Hu S, Zhu X, Triggs JR, et al. Inflammation-induced, 3'UTR-dependent translational inhibition of Hsp70 mRNA impairs intestinal homeostasis. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G1003-G1011.
19. Vetrano S, Rescigno M, Cera MR, et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology. 2008; 135: 173-184. (Pubitemid 351899025)
20. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238-249.
21. Pizarro TT, Arseneau KO, Bamias G, et al. Mouse models for the study of Crohn's disease. Trends Mol Med. 2003; 9: 218-222. (Pubitemid 36713392)
22. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 4: 7668-7672. (Pubitemid 39446893)
23. Fattal E, Vauthier C, Aynie I, et al. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J Control Release. 1998; 53: 137-143. (Pubitemid 28218697)
24. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004; 32: e149.
25. Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res. 2006; 23: 892-900. (Pubitemid 43781397)
26. Garg NK, Mangal S, Khambete H, et al. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul. 2010; 4: 114-128.
27. Park JH, Saravanakumar G, Kim K, et al. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010; 62: 28-41.
28. Krishna AD, Mandraju RK, Kishore G, et al. An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One. 2009; 4: e7240.